![In a 14:1 vote, ODAC nixes a PD-1 drug developed in China; data not generalizable to U.S. population](https://cdn.cancerletter.com/media/2022/02/11161504/48-06-odac-4x3-1.jpg)
![In a 14:1 vote, ODAC nixes a PD-1 drug developed in China; data not generalizable to U.S. population](https://cdn.cancerletter.com/media/2022/02/11161504/48-06-odac-4x3-1.jpg)
Cover Story
Regulatory News
In a 14:1 vote, ODAC nixes a PD-1 drug developed in China; data not generalizable to U.S. population
By Paul Goldberg and Alice Tracey
The FDA Oncologic Drugs Advisory Committee expressed decisive support for the agency’s view that data from trials of checkpoint inhibitors performed in mainland China aren’t applicable to the U.S. population.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Proposed rule by CMS would expand access to cancer treatment at tribal facilities
- Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.” - A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital